Cartesian Therapeutics, INC DEF 14A proxy statements

Cartesian Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 12, 2026, to elect directors, approve executive compensation, and ratify auditor appointments.

Cartesian Therapeutics, Inc. has filed a definitive proxy statement with the SEC, related to an upcoming shareholder meeting.

Cartesian Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 13, 2025, to vote on the election of directors, executive compensation, and the ratification of the company's independent auditor.

Cartesian Therapeutics is holding a special meeting on September 20, 2024, to seek stockholder approval for the conversion of its Series B Preferred Stock into common stock.

Cartesian Therapeutics is asking stockholders to approve an amended and restated 2016 Incentive Award Plan to increase the number of shares available for equity-based compensation.

Cartesian Therapeutics, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.